Risankizumab for the treatment of moderate-to-severe psoriasis: Real-world data from the Czech Republic BIOREP Registry

The study included 405 risankizumab patients with moderate-to-severe psoriasis. Patients were predominantly male (65.7%); mean time from diagnosis to initiation of risankizumab therapy was 23.8 years. Psoriatic arthritis was present in 22.5% of patients. A total 44.6% patients were naïve to targeted therapy. Of the experienced patients, most initiated risankizumab as 2nd line (26.6%); 17.0% as 3rd line and 11.8% as 4th and higher line. The mean PASI at baseline was 16.9 (SD 7.8) and was decreased to 1.6 (SD 2.9) after 4 months. The mean PASI < 1 remained stable until 36 months. Similarly, a decrease in DLQI was observed at 4 months from 14.8 (SD 6.4) to 1.9 (SD 3.6) with average values close to 1 until 36